AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 101 min read$BCAX

Cohlhepp Ryan sold $401K of BCAX

Cohlhepp Ryan (President, COO & Interim CEO) sold 17,500 shares of Bicara Therapeutics Inc. (BCAX) at an average of $22.90 ($22.77–$23.43, $0.40M total) across 2 trades on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cohlhepp Ryan
Published Sep 10, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BCAX
Neutral
medium confidence
Mentioned
$BCAX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BCAXNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, offering limited actionable insight.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming dilution from future financing rounds

Relevance 3/10Novelty 4/10Timing: filed after market close on Sep 10

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on insider holdings.

Company-level read

Ticker impact

$BCAXNeutralMedium confidence
Context

President/COO sold ~ $401K of shares via 10b5-1 plan

Expected impact

Limited short-term impact; may cause slight downward pressure

Evidence & confidence

Sale amount is small relative to market cap and follows a pre‑arranged plan, reducing informational value

Market effects

Sector

None beyond the company

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider could be cashing out ahead of upcoming clinical data release

Key entities

  • Company
    Bicara Therapeutics Inc.

    Biotech firm developing therapies for rare diseases

  • Insider
    Cohlhepp Ryan

    President, COO & Interim CEO of Bicara Therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BCAX insider trading history →

Related articles

AUG 18
$BCAXMed

Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript

Bicara Therapeutics (BCAX) reported Q2 2026 earnings, highlighting $497.3M in cash and marketable securities, a net loss of $55.4M, and R&D expenses of $45.8M. The company is on track for FORTIFI-HN01 study enrollment by year-end 2026, with interim analysis expected in mid-2027. Management discussed leadership transitions and strategic focus on HPV-negative head and neck cancer, as well as exploratory colorectal cancer cohorts.

fool.com7 min
AUG 12
$BCAXMed

Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances

Bicara Therapeutics (NASDAQ:BCAX) shares rose about 3.3% pre-market after the company said enrollment is progressing in its pivotal FORTIFI-HN01 study and it remains on track for an interim analysis in mid-2027. Bicara reported Q2 2026 net loss of $55.4M, or $0.82 per share, with higher R&D and G&A. Cash and securities were $497.3M, expected to fund operations into 1H 2029.

yahoo.com4 min
AUG 11
$BCAXMed

Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

Bicara Therapeutics (Nasdaq: BCAX) reported Q2 2026 progress and announced leadership changes. Ryan Cohlhepp will become CEO effective Jan 2027, succeeding Claire Mazumdar, who will move to Vice Chair and Strategic Advisor. Tanya Green becomes COO, and Jenn Larson becomes CFO. The company said it is on track for year-end enrollment in the FORTIFI-HN01 pivotal trial, with interim topline results expected mid-2027.

finanznachrichten.de6 min
AUG 11
$BCAXMed

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

Bicara Therapeutics Inc. (BCAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire

SEC EDGAR 8-K6 min